An open label randomized comparative clinical study to evaluate the efficacy of Zasdamrut in Acute Upper Respiratory Tract Infections

Upper respiratory Tract infection (URTIs) is one of the most common diseases among adults, who generally experience infections for two to five times a year. Upper respiratory tract infections such as laryngitis, pharyngitis, nasopharyngitis, and rhinitis, are among the most common diseases in primary medical care. The majority of URTI’s are of viral origin, due to rhinovirus, parainfluenza virus, corona virus, adenovirus, coxsackie virus, and influenza virus. Only 10% of URTI has beenattributed to bacterial etiology. The management of URTI of viral origin involvessymptomatic treatment like antihistamines, antipyretics or anti-inflammatory agents, coughsuppressants, expectorants and decongestants. Antibiotic treatment is beneficial only if symptoms persist for 10-14 days without improvement. Hence it poses a challenge to the clinicians to differentiate between viral and bacterial origin of URTI. In India, several studies have reported that 45% to 86% of URTI cases are treated with antibiotics. This is despite large amounts of evidence on the self-limiting nature of acute URTI. Problems associated with the overuse of antibiotics include development of bacterial resistance, increasing the burden of chronic disease, raising the cost of health services and the development of side effects. Hence there is need of better alternative treatment for the management of URTI. In this study, Zasdamrut tablet will be given to the patients with URTI for 7 days, and assessment will be done on the basis of Jackson Downing scale and on different blood parameters.